idecabtagene vicleucel
bms,2seventy bio
['mmsm', 'karmma']
biallelic loss of bcma caused a patient with #myeloma to relapse after treatment with anti-bcma #cartcells in the karmma trial. baseline heterozygous #bcma deletions might be a risk factor for treatment resistance #immunotherapy #mmsm #ash22 
Nature Medicine is a research journal devoted to publishing the latest advances in translational and clinical research for scientists and physicians.